Tumour immunomodulation: Mucins in resistance to initiation and maturation of immune response against tumours

Scandinavian Journal of Immunology

Volumn 78, Issue 1, 2013, Pages 1-7

  Anandkumar, A ^a   Devaraj, H ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; CYTOKINE; GALECTIN 1; MUCIN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CELL MATURATION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; T LYMPHOCYTE; TARGET CELL; TUMOR CELL DESTRUCTION;

EID: 84880279165     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12019     Document Type: Review

References (74)

1. Rose MC, Voynow JA. Respiratory Tract Mucin Genes and Mucin Glycoproteins in Health and Disease. Physiol Rev 2006;86:245-78.
2. Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
3. Babu SD, Jayanthi V, Devaraj N et al. Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer 2006;5:10.
4. Ganesh IM, Subramani D, Halagowder D. Mucin glycoarray in gastric and gallbladder epithelia. J Carcinog 2007;6:10.
5. Devaraj H, Anand KumarA, Niranjali D. Helicobacter pylori - infected neoplastic gastric epithelium: expression of MUC2 as a biomarker. In: Hayat MA, ed. Methods of Cancer Diagnosis, Therapy and Prognosis Vol 3; ISBN: 978-1-4020-8899-5, Netherlands: Springer International publication, 2009:121-36.
6. Ryan SO, Vlad AM, Islam K et al. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. J Biol Chem 2009;390:611-8.
7. Wilkie S, Picco G, Foster J et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-9.
8. Wu YM, Nowack DD, Omenn GS, Haab BB. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009;8:1876-86.
9. Picco G, Julien S, Brockhausen I et al. Over-expression of ST3Gal-I promotes mammary tumourigenesis. Glycobiology 2010;20:1241-50.
10. Baldus SE, Hanisch F. Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia. Adv Cancer Res 2000;79:201-48.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
12. Boland CR, Deshmukh GD. The carbohydrate composition of mucin in colonic cancer. Gastroenterology 1990;98:1170-7.
13. Van Elssen CH, Frings PW, Bot FJ et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 2010;57:597-606.
14. Vavasseur F, Dole K, Yang J et al. O-glycan biosynthesis in human colorectal adenoma cells during progression to cancer. Eur J Biochem 1994;222:415-24.
15. Granovsky M, Bielfeldt T, Peters S et al. UDPgalactose:glycoprotein-N-acetyl-D-galactosamine 3-beta-D-galactosyltransferase activity synthesizing O-glycan core 1 is controlled by the amino acid sequence and glycosylation of glycopeptide substrates. Eur J Biochem 1994;221:1039-46.
16. Axelsson MA, Karlsson NG, Steel DM et al. Neutralization of pH in the Golgi apparatus causes redistribution of glycosyltransferases and changes in the O-glycosylation of mucins. Glycobiology 2001;11:633-44.
17. Sewell R, Backstram M, Dalziel M et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006;281:3586-94.
18. Campbell BJ, Rowe GE, Leiper K et al. Increasing the intra-Golgi pH of cultured LS174T goblet-differentiated cells mimics the decreased mucin sulfation and increased Thomsen-Friedenreich antigen (Gal beta1-3GalNac alpha-) expression seen in colon cancer. Glycobiology 2001;11:385-93.
19. Wu C, Guo X, Wang W et al. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer 2010;10:123.
20. Delmotte P, Degroote S, Lafitte JJ et al. Tumor necrosis factor alpha increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis × epitopes in the human bronchial mucosa. J Biol Chem 2002;277:424-31.
21. Yokoigawa N, Takeuchi N, Toda M et al. Enhanced production of interleukin 6 in peripheral blood monocytes stimulated with mucins secreted into the bloodstream. Clin Cancer Res 2005;11:6127-32.
22. Chandrasekaran EV, Xue J, Neelamegham S et al. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans. Carbohydr Res 2006;341:983-94.
23. Park J-H, Nishidate T, Kijima K et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetyl galactosaminyl transferase 6 in mammary carcinogenesis. Cancer Res 2010;70:2759-69.
24. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
25. Kato K, Takeuchi H, Kanoh A et al. Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis. Glycoconj J 2010;27:267-76.
26. Chen D, Koido S, Li Y et al. T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat 2000;60:107-15.
27. Agrawal B, Krantz MJ, Reddish MA et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-9.
28. Melnick M, Chen H, Zhou Y et al. An alternatively spliced Muc10 glycoprotein ligand for putative L-selectin binding during mouse embryonic submandibular gland morphogenesis. Arch Oral Biol 2001;46:745-57.
29. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
30. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
31. Kotera Y, Fontenot JD, Pecher G et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60.
32. Lloyd KO, Burchell J, Kudryashov V et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 1996;271:33325-34.
33. Croce MV, Isla-Larrain MT, Capafons A et al. Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 2001;69:1-11.
34. Barnd DL, Lan MS, Metzgar RS et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-63.
35. Karsten U, Serttas N, Paulsen H et al. Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 2004;14:681-92.
36. Grinstead JS, Schuman JT, Campbell AP. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study. Biochemistry 2003;42:14293-305.
37. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS et al. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003;33:3242-54.
38. Ninkovic T, Kinarsky L, Engelmann K et al. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 2009;47:131-40.
39. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003;100:15029-34.
40. Apostolopoulos V, Karanikas V, Haurum JS et al. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997;159:5211-8.
41. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-74.
42. Kontani K, Taguchi O, Narita T et al. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001;84:1258-64.
43. Koukourakis MI, Giatromanolaki A, Guddo F et al. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. J Immunother 2000;23:104-14.
44. Apostolopoulos V, Loveland BE, Pietersz GA et al. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995;155:5089-94.
45. Carlos CA, Dong HF, Zack Howard OM et al. Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity. J Immunol 2005;175:1628-35.
46. Rughetti A, Pellicciotta I, Biffoni M et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 2005;174:7764-72.
47. Monti P, Leone BE, Zerbi A et al. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 2004;172:7341-9.
48. Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 1996;2:1367-70.
49. Mukherjee P, Ginardi AR, Madsen CS et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001;18:931-42.
50. Patankar MS, Jing Y, Morrison JC et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 2005;99:704-13.
51. Ogata S, Koganty R, Reddish M et al. Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj J 1998;15:29-35.
52. Nonaka M, Ma BY, Murai R et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells. J Immunol 2008;180:3347-56.
53. Seelenmeyer C, Wegehingel S, Lechner J et al. The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci 2003;116:1305-18.
54. Nguyen JT, Evans DP, Galvan M et al. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 2001;167:5697-707.
55. Perillo NL, Pace KE, Seilhamer JJ et al. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9.
56. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004;279:4705-12.
57. Bresalier RS, Byrd JC, Wang L et al. Colon cancer mucin: a new ligand for the beta-galactoside-binding protein galectin-3. Cancer Res 1996;56:4354-7.
58. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996;93:6737-42.
59. Yu LG, Andrews N, Zhao Q et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 2007;282:773-81.
60. Gubbels JA, Felder M, Horibata S et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010;9:11.
61. Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res 1999;59:2229-36.
62. Ragupathi G, Liu NX, Musselli C et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174:5706-12.
63. Murdoch WJ, Van Kirk EA, Smedts AM. Complement-inhibiting effect of ovarian cancer antigen CA-125. Cancer Lett 2006;236:54-7.
64. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993;151:767-76.
65. Grosso JF, Herbert LM, Owen JL et al. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J Immunol 2004;173:1721-30.
66. Burgel PR, Lazarus SC, Tam DC et al. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. J Immunol 2001;167:5948-54.
67. Takeyama K, Dabbagh K, Jeong Shim J et al. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000;164:1546-52.
68. Wright SE, Rewers-Felkins KA, Quinlin IS et al. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest 2008;37:215-25.
69. - natural killer T cells specific for MUC1 mucin. Cancer Res 2004;64:1171-80.
70. Takahashi T, Makiguchi Y, Hinoda Y et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994;153:2102-9.
71. Noto H, Takahashi T, Makiguchi Y et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 1997;9:791-8.
72. + T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998;10:1907-16.
73. Rosenblatt J, Wu Z, Vasir B et al. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother 2010;33:155-66.
74. Lakshminarayan V, Thompson P, Wolfert MA et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. PNAS 2012;109:261-6.